香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 和鉑醫藥控股有限公司 HBM Holdings Limited （於開曼群島註冊成立的有限公司） 根據協議條款，輝瑞將獲得諾納生物專有HCAb平台的全球使用權，以開發全人 源僅重鏈抗體。諾納生物將獲得首付款，並有權獲得監管、臨床及商業里程碑付 款。此外，諾納生物可與輝瑞合作，利用諾納生物的HCAb平台、先進的B細胞篩 選技術及綜合服務開展抗體發現、開發及工程。 警示聲明 我們無法保證我們或合作夥伴將能成功開發或最終銷售本公告所提述的任何候選 產品。本公司股東及潛在投資者於買賣本公司股份時務請審慎行事。 承董事會命 和鉑醫藥控股有限公司 主席兼執行董事 王勁松博士 （股份代號：02142） 自願公告 與輝瑞訂立非獨家授權協議 本公告由和鉑醫藥控股有限公司（「本公司」，連同其附屬公司統稱「本集團」）自願 作出，以告知本公司股東及潛在投資者有關本集團的最新業務更新。 本公司董事會（「董事會」）欣然宣佈，本公司 ...

Policy Developments - The National Health Commission's Director Lei Haichao emphasized the importance of planning for the "14th Five-Year Plan" to accelerate the construction of a healthy China and promote high-quality population development [2] - Key tasks include optimizing the function and layout of medical institutions, implementing strong foundational healthcare projects, and enhancing public health capabilities [2] Pharmaceutical Industry Updates - Bai Cheng Pharmaceutical's subsidiary received clinical trial approval for BIOS2242, a drug for treating acute ischemic stroke, with no current approvals for this product domestically or internationally [5] - Fosun Pharma's subsidiary received FDA approval for HLX11, a biosimilar drug for HER2-positive breast cancer, with applications for registration in China and Europe also accepted [6] Market Movements - Kexing Pharmaceutical's controlling shareholder plans to transfer 5% of its shares through an inquiry-based transfer due to operational needs [8][9] - Enwei Pharmaceutical announced a 20 million yuan investment to establish a fund focused on healthcare and technology sectors, with a total fund size of 201 million yuan [10] Major Industry Events - Guangxi's pharmaceutical exports reached a record high, with a year-on-year increase of 27.23% in the first three quarters of the year [13] - Samsung Medical's subsidiary is a candidate for a procurement project with an estimated value of 168 million yuan, which could positively impact the company's performance [14] Corporate Governance Changes - Haocen Medical announced a change in control, with no single controlling party, following the termination of a cooperation agreement [16] - Yifeng Pharmacy's executives plan to reduce their holdings by a total of 0.0176% of shares due to personal financial needs [17]

Policy Developments - The National Health Commission's Secretary Lei Haichao conducted research in Guangxi, focusing on pediatric and mental health, grassroots medical services, and public hospital reforms, emphasizing the need for a robust health system and high-quality population development [2] - The "14th Five-Year" plan highlights strengthening grassroots healthcare, promoting the distribution of quality medical resources, and enhancing public health capabilities [2] Drug and Medical Device Approvals - Baicheng Pharmaceutical's subsidiary received clinical trial approval for BIOS2242, a treatment for acute ischemic stroke, with no prior approvals for this product globally [5] - Fosun Pharma's subsidiary received FDA approval for HLX11, a biosimilar for HER2-positive breast cancer, with applications pending in China and Europe [6] Capital Market Activities - Kexing Pharmaceutical's controlling shareholder plans to transfer 5% of its shares, citing operational needs, with the transfer process managed by China International Capital Corporation [8] - Enwei Pharmaceutical announced a 20 million yuan investment in a venture capital fund focusing on healthcare and technology, with potential uncertainties regarding returns [10] - Pfizer completed the acquisition of Metsera for $10 billion, a company focused on developing drugs for obesity and cardiovascular diseases [11] Industry Developments - Guangxi's pharmaceutical exports reached a record high, growing 27.23% year-on-year in the first three quarters [13] - Samsung Medical's subsidiary is a candidate for a 168 million yuan procurement project with the State Grid, which could positively impact the company's performance [14] Shareholder Movements - Haocen Medical announced a change in control, with no single controlling party, following a partnership agreement termination [16] - Yifeng Pharmacy executives plan to reduce their holdings by a combined 0.0176% of shares due to personal financial needs [17][18]

Group 1: Hong Kong Consumer Services Investment Strategy - The report emphasizes the importance of capturing certainty and focusing on marginal improvements in the Hong Kong consumer services sector for 2026 [2][8] - Macau gaming revenue shows resilience, with October gross gaming revenue increasing by 16% year-on-year, reaching the highest monthly record post-pandemic, driven by relaxed visa policies and events like concerts [2][8] - The report highlights the growth in VIP gaming revenue, which increased by 29% year-on-year, recovering to 54% of 2019 levels, while mass gaming revenue grew by 7% year-on-year, up 15% compared to 2019 [2][8] - The current EV/EBITDA valuation for the industry is at a low of 9 times, indicating potential for investment [2][8] - Recommended stocks include Galaxy Entertainment, MGM China, and Sands China [2][8] Group 2: Online Travel Sector - Online travel companies are experiencing revenue growth that outpaces the overall travel market, benefiting from increased online penetration and a focus on leisure travel rather than business travel [2][8] - Ctrip and Tongcheng Travel have not been adversely affected by new competitors, with improved marketing efficiency and higher growth rates in outbound and pure overseas travel segments [2][8] Group 3: Restaurant Sector - The restaurant sector faces fundamental pressures but continues to trend towards increased chain penetration, with significant elasticity expected if consumer sentiment improves [3][9] - The report recommends focusing on marginal changes in companies, highlighting ready-to-drink tea brands like Gu Ming and Mi Xue, as well as franchise models in lower-tier markets like Guo Quan [3][9] - Notable companies with strong shareholder returns include Yum China, which achieved record net openings for KFC and Pizza Hut in the third quarter [3][9] Group 4: Higher Education Sector - The report discusses the maturation of conditions for profit-oriented classification management in higher education, with expectations for a turnaround in the fortunes of higher education companies [4][13] - Recent policy developments in Guangdong province regarding private higher education classification management are anticipated to be followed by other provinces, enhancing the operational asset rights of listed private higher education companies [4][14] - The report predicts that after five years of quality improvement investments, the operational efficiency of higher education companies is expected to gradually recover, with a focus on quality enhancement as a regulatory goal [5][15] Group 5: Dividend Returns in Higher Education - The report anticipates a resumption of expansion for higher education companies once quality standards are met, leading to revenue growth and valuation increases [6][16] - With a current payout ratio of 30% and low valuation multiples, some higher education companies are expected to offer dividend yields exceeding 9%, providing a good margin of safety [6][16] - Recommended stocks include Yuhua Education, Zhongjiao Holdings, New Higher Education Group, and others [6][16] Group 6: Investment Analysis in Higher Education - The report suggests focusing on Hong Kong higher education companies, as the potential for profit-oriented classification is expected to revive expansion dynamics [20][31] - The report also highlights the positive performance of autumn enrollment data for K12 education companies, indicating strong brand appeal among students [20][31] - Recommendations include New Oriental, TAL Education, and others, with a particular emphasis on vocational education companies like China Oriental Education [20][31]

Core Viewpoint - Avadel Pharmaceuticals has received an unsolicited acquisition proposal from H. Lundbeck A/S at a price of $23.00 per share, which includes $21.00 in cash and potential additional cash payments based on future sales of LUMRYZ™ and valiloxybate [1][7]. Group 1: Acquisition Proposal Details - The Lundbeck proposal includes a cash payment of $21.00 per share and a contingent value right (CVR) that could provide an additional $1.00 per share if certain sales milestones are met by specified dates [1]. - The total value of Lundbeck's proposal is approximately $2.25 billion [7]. - Avadel's board has determined that the Lundbeck proposal may be considered a "superior proposal" compared to its existing agreement with Alkermes, which offers $20.00 per share, consisting of $18.50 in cash and a CVR of $1.50 [2][7]. Group 2: Current Status and Implications - Avadel's board is currently reviewing the Lundbeck proposal and has been authorized to provide information and engage in discussions with Lundbeck, but cannot terminate the existing agreement with Alkermes [3][7]. - Alkermes has stated that it is considering its options following Lundbeck's proposal and emphasized that Avadel must first negotiate with Alkermes before accepting any alternative offers [7][9]. - Avadel shareholders are not required to take any action at this time as discussions are ongoing [6]. Group 3: Strategic Context - Lundbeck is shifting its operational model towards a partnership approach, focusing on higher-value innovative drug products, which aligns with its recent strategic adjustments [10]. - The competitive landscape is highlighted by a recent bidding war involving another biotech company, Metsera, indicating a trend of increased acquisition activity in the sector [10].

Core Viewpoint - The article discusses the surge in IPO applications from pharmaceutical companies in Hong Kong, highlighting the competitive landscape and the challenges faced by these companies in securing investors amid a crowded market [3][5][10]. Group 1: IPO Market Dynamics - As of November 14, 2023, 23 healthcare companies have successfully listed on the Hong Kong stock market this year, compared to only 8 in the same period last year [3]. - Over 40 healthcare companies have applied for IPOs in Hong Kong this year, with 8 applications submitted in just the first half of November [3]. - The increase in IPO applications has led to heightened competition among companies to attract suitable investors, resulting in a more complex negotiation landscape between companies and institutional investors [3][5]. Group 2: Case Study of Baillie Gifford - Baillie Gifford's planned global offering was delayed due to market conditions, with reports suggesting that investor demand did not meet expectations [4][5]. - The company aimed to attract long-term value investors rather than those focused on short-term price fluctuations, indicating a strategic approach to its IPO [5][6]. - The IPO process involves cornerstone placements, book-building, and public offerings, with cornerstone investors playing a crucial role in validating the company's value [6]. Group 3: Market Sentiment and Trends - The pharmaceutical sector has seen significant stock price increases this year, leading investors to focus on new IPOs rather than existing stocks [7]. - The introduction of new IPO pricing mechanisms by the Hong Kong Stock Exchange has increased the participation of cornerstone investors in pharmaceutical IPOs [9]. - Despite a recent cooling in the secondary market, the enthusiasm for IPO applications remains strong, with expectations of multiple companies going public in the first quarter of the following year [10][11]. Group 4: Investment Focus Areas - Certain sectors within the pharmaceutical industry, such as siRNA and ADC drugs, are attracting more attention from investors, indicating a trend towards specialized investment opportunities [11]. - The competition among major pharmaceutical companies for acquisitions, particularly in the GLP-1 drug space, has heightened interest in related IPOs [11]. - The article notes that while many IPOs are being pursued, the quality of the offerings and their pricing will be critical in attracting investor interest [13].

Group 1 - The CITIC Pharmaceutical Index increased by 3.29%, outperforming the CSI 300 Index by 4.37 percentage points, ranking 3rd among 30 primary industries [1] - The top ten stocks with the highest gains this week include Jindike, Renmin Tongtai, Chengda Pharmaceutical, Hefuchina, Fuxiang Pharmaceutical, Te Yi Pharmaceutical, Yao Yigou, Bohui Innovation, Shuyupingmin, and Haichen Pharmaceutical [1] - The top ten stocks with the largest declines this week include *ST Changyao, Zhend Medical, Heyuan Biological-U, Weigao Blood Purification, Furui Shares, Ruimaite, Microelectrophysiology, Botuo Biological, Bibete-U, and Shuoshi Biological [1] Group 2 - On November 10, Guangshentang Pharmaceutical's core drug, the oral small molecule hepatitis B surface antigen inhibitor GST-HG131, had its Phase II clinical data selected for the AASLD annual meeting's latest breakthrough summary and was reported on-site [1] - GST-HG131 is the first oral drug in global hepatitis B clinical breakthrough research that significantly reduces HBsAg in hepatitis B patients, with 76.5% of patients achieving levels below 100 IU/ml within three months, attracting attention from many multinational pharmaceutical companies for potential collaboration [1] Group 3 - On November 10, Roche announced that its third-generation BTK inhibitor Fenebrutinib met primary endpoints in two Phase III studies (FENhance 2 and FENtrepid) for treating relapsing multiple sclerosis (RMS) [2] - Results showed that at week 96, the annualized relapse rate (ARR) for patients on Fenebrutinib was significantly lower compared to those on teriflunomide, and at week 120, Fenebrutinib was non-inferior to Ocrevus in delaying disability progression in primary progressive multiple sclerosis (PPMS) patients [2] - Pfizer announced the successful completion of its $9.2 billion acquisition of Metsera, a biopharmaceutical company focused on developing next-generation treatments for obesity and cardiovascular metabolic diseases [2] - This acquisition adds a series of potential candidates highly complementary to Pfizer's existing internal medicine pipeline, including MET-097i, a weekly or monthly injectable GLP-1 receptor agonist entering Phase III trials, and MET-233i, a monthly amylin analog currently in Phase I evaluation [2]

Core Viewpoint - The article focuses on the innovative pipeline layout of Xinlitai in the CKM (Cardio-Kidney-Metabolic) field, emphasizing the company's strategic focus on chronic diseases related to cardiovascular health, kidney function, and metabolic disorders [13][18]. Market Review - The CITIC Pharmaceutical Index rose by 3.29%, outperforming the CSI 300 Index by 4.37 percentage points, ranking third among CITIC's 30 primary industries [8]. - The top ten stocks by growth this week included Jindike, Renmin Tongtai, and Chengda Pharmaceutical, while the bottom ten included *ST Changyao and Zhendai Medical [8]. Overall Perspective and Investment Themes - The innovative drug sector is transitioning from a quantity-driven logic to a quality-driven logic, with a focus on differentiated and internationalized pipelines expected to yield profitable products by 2025 [10]. - In the medical device sector, there is a notable recovery in bidding volumes for imaging equipment, and the home medical device market is benefiting from subsidy policies [10]. - The CXO and life sciences services sector is anticipated to see a rebound in domestic financing, with a trend towards high growth expected to return [10]. - The pharmaceutical industry is expected to enter a new growth cycle, particularly in the specialty raw materials sector, with a focus on patent expirations and vertical expansion of formulations [10]. Company-Specific Insights - Xinlitai currently has six innovative drugs on the market, with innovative drug revenue expected to exceed 50% by the end of 2025, driven by strong growth in products like Xinlitai and Fuli [12][16]. - The company is focusing on a comprehensive pipeline addressing various stages of CKM syndrome, with over 50 products in development targeting cardiovascular diseases, chronic kidney disease, and metabolic disorders [17][21]. - Xinlitai's internationalization strategy includes establishing a subsidiary in the U.S. (Salubris Bio) to enhance its global competitive edge [30]. Pipeline Development - The CKM pipeline includes drugs targeting obesity, hypertension, and chronic kidney disease, with a focus on innovative mechanisms and new targets for lipid management [25][27]. - The company is advancing multiple projects in various clinical phases, with significant milestones expected in the coming years [29][34]. Investment Recommendations - The medical device sector is expected to benefit from a recovery in bidding for imaging equipment and the growth of home medical devices due to government subsidies [40]. - The life sciences services sector is showing signs of recovery, with increasing demand and a focus on domestic product replacement [46].

Core Viewpoint - The surge in IPO applications from pharmaceutical companies in Hong Kong has created a competitive environment, leading to challenges in securing cornerstone investors and achieving favorable pricing for new listings [1][2][3]. Group 1: IPO Market Dynamics - The Hong Kong IPO market for healthcare has seen a significant recovery, with 23 companies successfully listed this year compared to only 8 last year [1]. - Over 40 healthcare companies have applied for IPOs this year, with 8 applications submitted in just the first half of November [1]. - The competition among companies to attract suitable investors has intensified due to the increasing number of IPO applications [1][4]. Group 2: Case Study of Baillie Gifford - Baillie Gifford's IPO plans were delayed due to unfavorable market conditions and insufficient demand from cornerstone investors [2][3]. - The company aims to attract long-term investors who value growth potential rather than short-term price fluctuations [3]. - The IPO structure includes cornerstone placements, book-building placements, and public offerings, with cornerstone investors playing a crucial role in establishing market credibility [3]. Group 3: Investor Sentiment and Market Trends - The performance of the pharmaceutical sector has been strong, with many stocks experiencing significant gains, leading investors to focus on new IPOs rather than existing stocks [4][5]. - Despite a recent cooling in the secondary market, the enthusiasm for IPOs remains high, with many companies eager to secure reputable cornerstone investors [5][8]. - The market is witnessing a differentiation in investor interest, with certain sectors like siRNA and ADC drugs attracting more attention [7][8]. Group 4: Future Outlook - Several companies are expected to launch IPOs in the first quarter of next year, as they aim to capitalize on favorable market conditions [7]. - The IPO pricing strategy is critical, as investors are looking for sufficient discount space to engage with new offerings [8].

消息面上，三生制药在2025年STIC会议上公布707联合化疗治疗1LNSCLC的临床2期研究数据。此外， 辉瑞公布707全球临床策略，辉瑞与三生制药达成协议后，积极推进707的临床开发，并将707管线列为 其核心管线，目前已经提交5个新的临床申请，辉瑞的第二波开发计划预计在2026年底前将新增10个适 应症的临床试验和10种以上新型组合方案。 三生制药(01530)再涨近5%，截至发稿，涨4.03%，报35.14港元，成交额11.29亿港元。 华泰证券此前发布研报称，10月30日，根据Clinicaltrials披露，辉瑞注册了PF-08634404（SSGJ-707）的 两项全球三期临床试验（NSCLC和CRC），正式启动海外临床。该行认为辉瑞707全球临床开展速度超 市场预期，充分体现了FDA对中国创新药的认可，随着ADC联用等后续临床的逐步开展，有望持续催 化公司估值提升。 ...